Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|September 1, 2023
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancerJessica M Konen, B Leticia Rodriguez, Haoyi Wu, et al.
Cancers|April 17, 2019
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung CancerJessica M Konen, B Leticia Rodriguez, Jared J Fradette, et al.
Nature Communications|May 11, 2021
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancersDavid H Peng, B Leticia Rodriguez, Lixia Diao, et al.
Oncoimmunology|December 22, 2016
Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppressionLimo Chen, Xiaohui Yi, Sangeeta Goswami, et al.
JCI Insight|July 26, 2021
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancerAparna Padhye, Jessica M Konen, B Leticia Rodriguez, et al.
Frontiers in Immunology|July 14, 2023
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceB Leticia Rodriguez, Limo Chen, Yanli Li, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
Nature Communications|November 14, 2019
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancerRoxsan Manshouri, Etienne Coyaud, Samrat T Kundu, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 5, 2020
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell CarcinomaJose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, et al.
Pageof 4